Recent Quotes (30 days)

You have no recent quotes
chg | %

BTG plc  

(Public, LON:BTG)   Watch this stock  
Find more results forLON:BGC
750.00
+14.50 (1.97%)
Apr 21 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 736.30 - 751.00
52 week 508.50 - 835.87
Open 740.00
Vol / Avg. 800,470.00/650,667.00
Mkt cap 2,863.33M*
P/E 68.97
Div/yield     -
EPS 0.11*
Shares 381.78M
Beta     -
Inst. own     -
*GBP
Apr 2, 2015
BTG PLC Close Period Trading Statement Release for the year ended 31 March 2015
Feb 3, 2015
BTG PLC Investor Day
  

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 20.50% 8.36%
Operating margin 21.71% 9.40%
EBITD margin - 24.30%
Return on average assets 10.63% 3.87%
Return on average equity 14.07% 5.04%
Employees 776 -
CDP Score - 76 D

Address

5 Fleet Place
LONDON, EC4M 7RD
United Kingdom - Map
+44-20-75750000 (Phone)
+44-20-75750010 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

BTG plc is a United Kingdom-based specialist healthcare company focused on developing and commercializing products targeting acute care, cancer and vascular diseases. The Company operates in three business segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. Its Interventional Medicines include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots and patients with varicose veins in the great saphenous vein system of the leg. Its Specialty Pharmaceutical products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. Its Licensing business area consists of licensed products and programs and generates royalties for the company. The Company�s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd, BTG Employee Share Schemes Ltd and other.

Officers and directors

Dame Pamela Louise Makin Ph.D. Chief Executive Officer, Executive Director
Age: 54
Rolf B. Soderstrom Chief Financial Officer, Executive Director
Melanie G. Lee Ph.D., CBE Part Time Chief Scientific Officer
Age: 56
Paul Mussenden Company Secretary
Garry Andrew Watts MBE Non-Executive Chairman of the Board
Age: 58
Susan Elizabeth Foden Ph.D. Non-Executive Director
Age: 61
Giles F. B. Kerr Senior Independent Non-Executive Director
Ian F. R. Much Independent Non-Executive Director
W. James O'Shea Independent Non-Executive Director
Age: 63